Patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) who have to discontinue use of a kinase inhibitor can be salvaged by switching to an alternate drug in the same class. According to a retrospective US study of 178 CLL patients who discontinued either ibrutinib or idelalisib, the sequence of kinase inhibitors for those who switched did ...
Clear role for kinase inhibitors in CLL, says expert
By Mardi Chapman
29 Nov 2016